ANZCTR search results

This study assesses whether a Tai Chi-based stress reduction program, including two educational workshops on stress management and healthy lifestyle and 8-week Tai Chi, can reduce the stress, anxiety, and depression levels among university students. Participants will be randomly assigned to either the Tai Chi program or a waitlist control group, 20 in each group. We hypothesize that those in the Tai Chi group will report lower stress levels and enhanced overall health compared to the control group. Questionnaires and other vital measures will be tested at baseline and 8 weeks. We will also perform interviews with participants in the beginning and at the end of this study to understand their expectation and satisfaction towards this stress reduction program.

The aim of this project is to explore the effects of an acute bout of exercise (before and after a training intervention) and the chronic effects of a 12-week resistance vs aerobic training program on acute and resting expression of signalling proteins, known as myokines, and their cancer-suppressive effects, in relation to body composition, in breast cancer survivors. Who is it for? You may be eligible for this study if you are a woman with stage I-III breast cancer who has completed primary treatment at least 4 months prior to commencing this trial, and have been medically cleared for exercise. Study details Participants will be randomly allocated to a 12-week exercise program involving either resistance or aerobic training. In the weeks immediately before and after the 12-week program, participants will also complete an acute bout of exercise. Participants will be asked to provide blood and complete questionnaires and physical testing before and after the acute bouts of exercise and 12-week program. It is hoped that findings from this study shed light into the mechanisms behind exercise's effect on breast cancer management.

Women who have a diagnosis of gestational diabetes or hypertension in pregnancy are recommended to have further testing postpartum to review their longer term health risks; however, many women do not undergo testing in a timely manner due to many competing priorities. This study is evaluating whether an intervention providing administrative assistance can improve attendance and testing in the post partum period. Participants in the POST-IT study are randomly allocated to receive standard of care (usual advice with no administrative assistance) or intervention (assistance to book GP visit and recommended testing after GDM or HDP). Attendance rates, uptake of testing, and acceptability of the intervention will be evaluated at four months' postpartum via telephone survey.

The goals of this research project are to evaluate the implementation and effectiveness of an attachment-based and trauma-informed intervention for relative/kinship caregivers. The program is delivered in group format across 9 weekly 1.5 hr sessions and introduces caregivers to a set of attachment-informed principles relating to sensitive caregiving, child and youth development and family wellbeing. Overall, the program aims to reduce caregiver strain and promote caregivers' understanding of and sensitive responding to their child's attachment needs, and, in turn, strengthen the quality of the caregiver-child relationship and promote children's behavioural and socio-emotional wellbeing.

Glucocorticoids (GCs, also known as steroids or prednisolone) are often used to treat rheumatic diseases such as Rheumatoid Arthritis (RA), Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA), While they can relieve symptoms, they are also associated with many side effects including reduced life expectancy, infection, weight gain, hypertension, diabetes, osteoporosis, cataracts, mood disturbance, thin skin, and easy bruising. In recognition of this, Australian Living Guidelines for RA recommend against the long-term use of GCs. However, studies have shown that once GCs are started, they are often difficult to stop even when the joint disease of RA appears to be well-controlled. Reducing and stopping GCs is often difficult to achieve in the clinic setting, where there are insufficient resources to provide comprehensive education and support. There are no proven methods to improve implementation of these recommendations. The aim of this study is to develop a pharmacist-led GC intervention to assist with GC reduction and cessation and minimise the side effects associated with GC use in patients with rheumatic diseases compared to “usual care”. Rheumatologists will refer people with RA, PMR and GCA who require gradual reduction of GC dose and/or cessation. Patients will either receive the new pharmacist-led intervention or receive “usual care” in an existing routine clinic plus a written schedule for reducing the GC dose from the pharmacist. Patients in the new intervention arm will receive 4-weekly telehealth appointments or phone calls when the pharmacist will collect patient reported data on dose, side effects, and barriers to dose reduction. All participants will have face-to-face visits at baseline, 6 months, and 12 months, when additional information including height, weight, BMI, blood pressure, disease activity and relapse will be collected. The aim will be to see if the pharmacist-led intervention increases the likelihood of achieving the target GC dose at 6 months and reduces the overall GC dose, relapses/flares, side effects, ED presentations and hospitalisations.

We are doing this research to evaluate a new device intended to improve outcomes in patients undergoing laparoscopic hysterectomy and overall patient care. Historically, without contained tissue reduction, malignancy (cancer) can spread within the pelvic space. The Claria System is designed to capture, reduce, and remove uterine tissue without the spreading of potentially malignant (cancer) cells. This research study is intended to demonstrate the function of the new Claria System and its ability to successfully contain, morcellate, and remove uterine tissue during hysterectomy. Safety of the system will also be evaluated.

This study will assess safety and pharmacokinetics of inhaled (nebulised) TLB001 which is being developed as a potential treatment for idiopathic pulmonary fibrosis. It will be run as a single ascending dose (Part A) and multiple ascending dose (Part B) study. Participants will be residential in the unit for 3 (Part A) or 16 (Part B) nights, and also attend final study outpatient visits.

Sulforaphane is a naturally occurring compound found in cruciferous vegetables such as broccoli, and has potent anti-inflammatory and antioxidant effects. Sulforaphane is administered in the form of broccoli sprout supplements as they're cheap, room temperature stable and have a proven safety profile in clinical trials outside of pregnancy including cancer and autism spectrum disorder. This trial will use non-invasive clinical methodologies to assess the vasculature in women both before and after a dose of a broccoli sprout extract. We would like to recruit up to 30 women for this trial (non-pregnant, pregnant, pregnant with hypertension) to assess blood pressure, collect one blood sample, and assess flow mediated dilation. This will assess whether a single dose of a broccoli sprout extract has immediate effects on the vasculature. We hypothesise that a single dose of a broccoli sprout extract will not affect blood pressure but will increase flow-mediated dilation in all non-pregnant and pregnant women.

A large proportion (i.e., approximately 30%) of individuals with prediabetes develop type-2 diabetes. Improving glucose control by increasing regular physical activity can help to prevent diabetes, and for adults with poor sleep, improving sleep can also improve glucose control and strengthen the effect of physical activity. A 3-group randomised control trial to compare the effect of different digital interventions to improve lifestyle behaviours and the effect this has on glucose control in mid-aged adults (45-64 years). The three groups are a physical activity and sleep group, a physical activity only intervention and a control group. Outcomes will be assessed at 6 weeks, 12 weeks (primary endpoint), and 24 weeks after intervention commencement. The intervention program will provide participants continuous access to a mobile app and website for the 24-week study period, where participants can manually set and review goals, enter (i.e., self-monitor) their behavioural data on group-respective target behaviours, and view feedback, historical log data (i.e., representing progress over time) and educational materials.

This is a Phase 1b study to evaluate the safety and tolerability, PK/PD, and antiviral activity/efficacy of cavrotolimod and cavrotolimod-containing combinations in CHB infected subjects who are on nucleos(t)ide therapy. Cavrotolimod ± BJT-778 is being developed to address the high unmet medical need with possible benefits for participants with Chronic Hepatis B virus infection (CHB). This study will enroll non-cirrhotic, chronic hepatitis B (CHB) infected adults aged 18-65 years of age, inclusive, on nucleos(t)ide therapy. Part B will evaluate open-label, cavrotolimod plus BJT-778, HBsAg monoclonal antibody, in combination. Thi sStudy duration of Part B: Up to 52 weeks (up to 4 weeks for Screening, 24 weeks for treatment, and 12 to 24 weeks for follow up).